MacroGenics Q1 2025 net loss improves to $41M; cash runway into H2 2026

MACROGENICS INC

2025-Q1 EPS reported -$0.65 revenue$13,192,000

Net loss of $41.0M ($0.65 loss per share) vs Q1 2024 loss of $52.2M ($0.84).
Revenue $13.2M, up from $9.1M, driven by collaborative agreements and contract manufacturing; no product sales after MARGENZA sale.
Cash, equivalents and marketable securities $154.1M as of Mar 31, 2025, down from $201.7M at Dec 31, 2024; runway projected into H2 2026.
First patient dosed in Phase 2 LINNET study of lorigerlimab in platinum-resistant ovarian and clear cell gynecologic cancers.
LORIKEET Phase 2 (lorigerlimab + docetaxel in mCRPC) clinical update expected in second half of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.